Apotex
Coverage of Apotex in the Nexus archive.
- STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states
Sandoz agreed to pay $478.5 million to settle allegations of price-fixing generic drugs, including $400 million over seven years to states and $28.5 million to resellers. The company denied wrongdoing as part of a long-running legal battle with states and resellers over inflated drug prices.
- Minnesota joins $29.6M settlement over generic drug price fixing
Minnesota joined a $29.6 million nationwide settlement with Glenmark over allegations of price fixing in generic prescription drugs. The state's share is $187,000, part of over $560,000 recovered from settlements with multiple drug makers. Consumers who purchased drugs from these companies between 2009 and 2019 may be eligible for compensation.
- Apotex, Backers Raise $932 Million in Canada IPO Priced at Top
Apotex and its backers raised $932 million in a Canada IPO priced at the top. The offering was oversubscribed, reflecting strong investor demand.
- Drugmaker Apotex Files for Canada IPO Showing Revenue Jump
Drugmaker Apotex has filed for an initial public offering (IPO) in Canada, accompanied by a reported revenue increase. The company's Toronto-based facility is highlighted in the article.